BRCA1 and pancreatic ductal adenocarcinoma: Studies conducted using comprehensive genomic profiling (CGP) tests have revealed that approximately 20% of patients with pancreatic ductal adenocarcinoma show mutations in homologous recombination genes, including BRCA1/2 and PALB234,35.